Briefs: Granules India

Granules India received approval from Brazilian Health Regulatory Agency ANVISA

India’s MRI systems market to reach $950 million by 2030, forecasts GlobalData

India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023

ABB India bags automation order for Reliance Life Sciences' biopharmaceutical facilities

ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra

Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes

India's Medical Value sector projected to reach $ 13 billion by 2026: Dr Mandaviya

Need to harmonize traditional and modern medicine to combat alarming health problems

India is set to become the global hub of medical technology and devices: Dr Mandaviya

The medical device sector is considered as one of the sunrise sectors in the country

Abbott India's Q1 FY24 PAT up at Rs. 290.24 Cr

Abbott India has reported total income of Rs. 1535 crores during the period ended June 30, 2023

SMS Lifesciences India posts Q1 FY24 consolidated loss at Rs. 1.79 Cr

The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24

Granules India received USFDA approval for the ANDA filed for metoprolol succinate ER tablets